I also compare Clinuvel to other asx biotech stocks. They are profitable due to a failed strategy of inadequately reinvesting in their pipeline, possibly due to the board falling asleep during a dr wright presentation. However, Clinuvel are hopeless and embarrassing with respect to their communication, treatment of shareholders and ability to execute. Wolgen is extremely well paid ( tax free in Monaco) and speaks in riddles and unable to answer a direct question but allegedly delivers market sensitive information selectively during private discussions.
good luck with your investment
I also compare Clinuvel to other asx biotech stocks. They are...
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.08 |
Change
-1.300(7.48%) |
Mkt cap ! $831.2M | |||
| Open | High | Low | Value | Volume |
| $17.33 | $17.35 | $16.01 | $1.563M | 93.82K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 104 | $16.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.10 | 38 | 3 |
View Market Depth
| Last trade - 12.31pm 08/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |